Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H19FN4 |
Molecular Weight | 310.3687 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC2=C(NC(CN3CCN(CC3)C4=NC=CC=C4)=C2)C=C1
InChI
InChIKey=PQOIDBZLMJMYCD-UHFFFAOYSA-N
InChI=1S/C18H19FN4/c19-15-4-5-17-14(11-15)12-16(21-17)13-22-7-9-23(10-8-22)18-3-1-2-6-20-18/h1-6,11-12,21H,7-10,13H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10731629Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/16154186
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10731629
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/16154186
CP 226269 is a selective dopamine D4 agonist. This compound was developed by Pfizer for Neuroscience research. CP226269 showed a significant enhancement in the 5-trial inhibitory avoidance model.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10395213 |
6.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia. | 1999 May |
|
Topographically based search for an "Ethogram" among a series of novel D(4) dopamine receptor agonists and antagonists. | 2000 May |
|
Nigrostriatal dopaminergic denervation enhances dopamine D(4) receptor binding in rat caudate-putamen. | 2001 May-Jun |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10731629
0.2–25.0 mg/kg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10395213
Highly D4R-selective agonist CP-226269 stimulated PLM with an EC50 of 2.9 nM, comparable to its reported EC50 of 5.8 nM for inhibition of cAMP formation via D4Rs.
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
WX4CVT9DYH
Created by
admin on Sat Dec 16 19:05:29 GMT 2023 , Edited by admin on Sat Dec 16 19:05:29 GMT 2023
|
PRIMARY | |||
|
220941-93-5
Created by
admin on Sat Dec 16 19:05:29 GMT 2023 , Edited by admin on Sat Dec 16 19:05:29 GMT 2023
|
PRIMARY | |||
|
9796720
Created by
admin on Sat Dec 16 19:05:29 GMT 2023 , Edited by admin on Sat Dec 16 19:05:29 GMT 2023
|
PRIMARY | |||
|
DTXSID70430875
Created by
admin on Sat Dec 16 19:05:29 GMT 2023 , Edited by admin on Sat Dec 16 19:05:29 GMT 2023
|
PRIMARY | |||
|
CP-226,269
Created by
admin on Sat Dec 16 19:05:29 GMT 2023 , Edited by admin on Sat Dec 16 19:05:29 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD